IMVT - CIK 0001764013
Immunovant, Inc. trades as IMVT and has a market capitalization of $6.40 B, making it the #1222 largest US-listed company by market value. This page tracks Immunovant, Inc. through 611 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-22 |
| Insider sale notice | 144 | 2026-05-20 |
| Annual report | 10-K | 2026-05-20 |
| Major company event | 8-K | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
| Insider sale notice | 144 | 2026-05-01 |
| Insider trade | 4 | 2026-05-01 |
| Insider trade | 4 | 2026-04-24 |
The largest companies sharing Immunovant, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Immunovant, Inc. (IMVT) has a market capitalization of $6.40 B as of 2026-06-10, ranking #1222 among US-listed companies.
In its latest fiscal year Immunovant, Inc. reported a net loss of $505.61M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.